{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T07:34:30Z","timestamp":1776324870262,"version":"3.50.1"},"reference-count":168,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K06986"],"award-info":[{"award-number":["23K06986"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JERF TENKAN 21008"],"award-info":[{"award-number":["JERF TENKAN 21008"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012628","name":"Japan Epilepsy Research Foundation","doi-asserted-by":"publisher","award":["23K06986"],"award-info":[{"award-number":["23K06986"]}],"id":[{"id":"10.13039\/501100012628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012628","name":"Japan Epilepsy Research Foundation","doi-asserted-by":"publisher","award":["JERF TENKAN 21008"],"award-info":[{"award-number":["JERF TENKAN 21008"]}],"id":[{"id":"10.13039\/501100012628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Clozapine is listed as one of the most effective antipsychotics and has been approved for treating treatment-resistant schizophrenia (TRS); however, several type A and B adverse reactions, including weight gain, metabolic complications, cardiotoxicity, convulsions, and discontinuation syndromes, exist. The critical mechanisms of clinical efficacy for schizophrenia, TRS, and adverse reactions of clozapine have not been elucidated. Recently, the GABA isomer L-\u03b2-aminoisobutyric acid (L-BAIBA), a protective myokine in the peripheral organs, was identified as a candidate novel transmission modulator in the central nervous system (CNS). L-BAIBA activates adenosine monophosphate-activated protein kinase (AMPK) signalling in both the peripheral organs and CNS. Activated AMPK signalling in peripheral organs is an established major target for treating insulin-resistant diabetes, whereas activated AMPK signalling in the hypothalamus contributes to the pathophysiology of weight gain and metabolic disturbances. Clozapine increases L-BAIBA synthesis in the hypothalamus. In addition, the various functions of L-BAIBA in the CNS have recently been elucidated, including as an activator of GABA-B and group-III metabotropic glutamate (III-mGlu) receptors. Considering the expressions of GABA-B and III-mGlu receptors (localised in the presynaptic regions), the activation of GABA-B and III-mGlu receptors can explain the distinct therapeutic advantages of clozapine in schizophrenia or TRS associated with N-methyl-D-aspartate (NMDA) receptor disturbance compared with other atypical antipsychotics via the inhibition of the persistent tonic hyperactivation of thalamocortical glutamatergic transmission in the prefrontal cortex. L-BAIBA has also been identified as a gliotransmitter, and a detailed exploration of the function of L-BAIBA in tripartite synaptic transmission can further elucidate the pathophysiology of effectiveness for treating TRS and\/or specific adverse reactions of clozapine.<\/jats:p>","DOI":"10.3390\/biom13091288","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T10:06:48Z","timestamp":1692871608000},"page":"1288","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Novel Gliotransmitter, L-\u03b2-Aminoisobutyric Acid, Contributes to Pathophysiology of Clinical Efficacies and Adverse Reactions of Clozapine"],"prefix":"10.3390","volume":"13","author":[{"given":"Kouji","family":"Fukuyama","sequence":"first","affiliation":[{"name":"Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eishi","family":"Motomura","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9025-2548","authenticated-orcid":false,"given":"Motohiro","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Division of Neuroscience, Graduate School of Medicine, Mie University, Tsu 514-8507, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/bmb\/ldv017","article-title":"Antipsychotic medication in schizophrenia: A review","volume":"114","author":"Lally","year":"2015","journal-title":"Br. Med. Bull."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4103\/0253-7176.135365","article-title":"Schizophrenia and Other Psychotic Disorders in Diagnostic and Statistical Manual of Mental Disorders (DSM)-5: Clinical Implications of Revisions from DSM-IV","volume":"36","author":"Tandon","year":"2014","journal-title":"Indian J. Psychol. Med."},{"key":"ref_3","first-page":"167","article-title":"Schizofreniespectrum en andere psychotische stoornissen in de DSM-5","volume":"56","author":"Tan","year":"2014","journal-title":"Tijdschr. Voor Psychiatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2165\/00023210-199911040-00007","article-title":"Predicting response to clozapine","volume":"11","author":"Hu","year":"1999","journal-title":"CNS Drugs"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","article-title":"Clozapine: Balancing safety with superior antipsychotic efficacy","volume":"6","author":"Meltzer","year":"2012","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29823 Patients with Schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/15622970500483177","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: Long-term treatment of schizophrenia","volume":"7","author":"Falkai","year":"2006","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/15622975.2012.696143","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance","volume":"13","author":"Hasan","year":"2012","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/02698811231158232","article-title":"Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology","volume":"37","author":"Rogers","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/jamapsychiatry.2019.1702","article-title":"Association with Hospitalization and All-Cause Discontinuation Among Patients with Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies","volume":"76","author":"Masuda","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41386-019-0577-3","article-title":"Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: A meta-analysis","volume":"45","author":"Mizuno","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/cn400121z","article-title":"Classics in chemical neuroscience: Clozapine","volume":"4","author":"Wenthur","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"116049","DOI":"10.1016\/j.trac.2020.116049","article-title":"Evaluation of electrochemical methods for tonic dopamine detection in vivo","volume":"132","author":"Rusheen","year":"2020","journal-title":"TrAC Trends Anal. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","article-title":"Update on typical and atypical antipsychotic drugs","volume":"64","author":"Meltzer","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pharmthera.2015.01.005","article-title":"Clozapine and GABA transmission in schizophrenia disease models: Establishing principles to guide treatments","volume":"150","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/BF02245619","article-title":"Relapse following clozapine withdrawal: Effect of neuroleptic drugs and cyproheptadine","volume":"124","author":"Meltzer","year":"1996","journal-title":"Psychopharmacology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S0924-9338(10)71701-6","article-title":"From receptor pharmacology to improved outcomes: Individualising the selection, dosing, and switching of antipsychotics","volume":"25","author":"Correll","year":"2010","journal-title":"Eur. Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1021\/cn400189s","article-title":"Clozapine, a fast-off-D2 antipsychotic","volume":"5","author":"Seeman","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1001\/archpsyc.1997.01830220102017","article-title":"D2 dopamine receptor occupancy: A crossover comparison of risperidone with clozapine therapy in schizophrenic patients","volume":"54","author":"Su","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/schbul\/17.2.263","article-title":"The mechanism of action of novel antipsychotic drugs","volume":"17","author":"Meltzer","year":"1991","journal-title":"Schizophr. Bull."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10578-013-0390-x","article-title":"A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial","volume":"45","author":"Ghanizadeh","year":"2014","journal-title":"Child Psychiatry Hum. Dev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","author":"Maeda","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1021\/jm049632c","article-title":"Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents","volume":"48","author":"Fernandez","year":"2005","journal-title":"J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"ref_29","first-page":"102","article-title":"Active metabolites as antidepressant drugs: The role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders","volume":"4","author":"Alamo","year":"2013","journal-title":"Front. Psychiatry"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1124\/mol.106.024612","article-title":"Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor","volume":"70","author":"Smith","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref_33","first-page":"494","article-title":"In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone","volume":"41","author":"Leysen","year":"1992","journal-title":"Mol. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1017\/S0033291719000369","article-title":"The prevalence of agranulocytosis and related death in clozapine-treated patients: A comprehensive meta-analysis of observational studies","volume":"50","author":"Li","year":"2020","journal-title":"Psychol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/acps.13398","article-title":"Risk factors for clozapine-induced myocarditis and cardiomyopathy: A systematic review and meta-analysis","volume":"145","author":"Vickers","year":"2022","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: A systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2042098618756261","article-title":"Safety of antipsychotics for the treatment of schizophrenia: A focus on the adverse effects of clozapine","volume":"9","author":"Rapini","year":"2018","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Okada, M., Fukuyama, K., Shiroyama, T., and Murata, M. (2020). A Working Hypothesis Regarding Identical Pathomechanisms between Clinical Efficacy and Adverse Reaction of Clozapine via the Activation of Connexin43. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197019"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"20451253211032053","DOI":"10.1177\/20451253211032053","article-title":"Clozapine discontinuation withdrawal symptoms in schizophrenia","volume":"11","author":"Blackman","year":"2021","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41398-018-0192-9","article-title":"Review of withdrawal catatonia: What does this reveal about clozapine?","volume":"8","author":"Lander","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/j.1476-5381.2011.01638.x","article-title":"Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes","volume":"165","author":"Tanahashi","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Fukuyama, K., Kato, R., Murata, M., Shiroyama, T., and Okada, M. (2019). Clozapine Normalizes a Glutamatergic Transmission Abnormality Induced by an Impaired NMDA Receptor in the Thalamocortical Pathway via the Activation of a Group III Metabotropic Glutamate Receptor. Biomolecules, 9.","DOI":"10.3390\/biom9060234"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Fukuyama, K., Okubo, R., Murata, M., Shiroyama, T., and Okada, M. (2020). Activation of Astroglial Connexin is Involved in Concentration-Dependent Double-Edged Sword Clinical Action of Clozapine. Cells, 9.","DOI":"10.3390\/cells9020414"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Fukuyama, K., and Okada, M. (2021). Effects of Atypical Antipsychotics, Clozapine, Quetiapine and Brexpiprazole on Astroglial Transmission Associated with Connexin43. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115623"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"112750","DOI":"10.1016\/j.biopha.2022.112750","article-title":"Impact of 5-HT7 receptor inverse agonism of lurasidone on monoaminergic tripartite synaptic transmission and pathophysiology of lower risk of weight gain","volume":"148","author":"Fukuyama","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41537-023-00336-1","article-title":"Opposing effects of clozapine and brexpiprazole on beta-aminoisobutyric acid: Pathophysiology of antipsychotics-induced weight gain","volume":"9","author":"Fukuyama","year":"2023","journal-title":"Schizophrenia"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Fukuyama, K., Motomura, E., and Okada, M. (2023). Enhanced L-beta-Aminoisobutyric Acid Is Involved in the Pathophysiology of Effectiveness for Treatment-Resistant Schizophrenia and Adverse Reactions of Clozapine. Biomolecules, 13.","DOI":"10.3390\/biom13050862"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/JCP.0000000000000159","article-title":"A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses","volume":"34","author":"Kelly","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/archpsyc.58.12.1172","article-title":"Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: A claims-based approach","volume":"58","author":"Lund","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dc22-Sint","article-title":"Introduction: Standards of Medical Care in Diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e142243","DOI":"10.1172\/JCI142243","article-title":"Pharmacological treatment of hyperglycemia in type 2 diabetes","volume":"131","author":"Taylor","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4088\/JCP.v58n0304","article-title":"Clozapine and associated diabetes mellitus","volume":"58","author":"Popli","year":"1997","journal-title":"J. Clin. Psychiatry"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41398-020-0785-y","article-title":"Adjunctive metformin for antipsychotic-induced dyslipidemia: A meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"10","author":"Jiang","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.euroneuro.2016.07.010","article-title":"A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome","volume":"26","author":"Zimbron","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Siskind, D.J., Leung, J., Russell, A.W., Wysoczanski, D., and Kisely, S. (2016). Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0156208"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12991-020-00319-x","article-title":"Outcomes and safety of concomitant topiramate or metformin for antipsychotics-induced obesity: A randomized-controlled trial","volume":"19","author":"Wang","year":"2020","journal-title":"Ann. Gen. Psychiatry"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2147\/NDT.S113099","article-title":"Antipsychotic-associated weight gain: Management strategies and impact on treatment adherence","volume":"13","author":"Dayabandara","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/dom.13522","article-title":"Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis","volume":"21","author":"Siskind","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/schbul\/sbac001","article-title":"Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials","volume":"48","author":"Wu","year":"2022","journal-title":"Schizophr. Bull."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Fukuyama, K., Motomura, E., and Okada, M. (2023). Therapeutic Potential and Limitation of Serotonin Type 7 Receptor Modulation. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032070"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Carli, M., Kolachalam, S., Longoni, B., Pintaudi, A., Baldini, M., Aringhieri, S., Fasciani, I., Annibale, P., Maggio, R., and Scarselli, M. (2021). Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences. Pharmaceuticals (Basel), 14.","DOI":"10.3390\/ph14030238"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.neuroscience.2005.03.045","article-title":"Biphasic actions of topiramate on monoamine exocytosis associated with both soluble N-ethylmaleimide-sensitive factor attachment protein receptors and Ca(2+)-induced Ca(2+)-releasing systems","volume":"134","author":"Okada","year":"2005","journal-title":"Neuroscience"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1038\/emboj.2010.177","article-title":"An intimate liaison: Spatial organization of the endoplasmic reticulum-mitochondria relationship","volume":"29","author":"Scorrano","year":"2010","journal-title":"EMBO J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.bbamcr.2012.12.016","article-title":"IP3, a small molecule with a powerful message","volume":"1833","author":"Decrock","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","article-title":"Metformin: From mechanisms of action to therapies","volume":"20","author":"Foretz","year":"2014","journal-title":"Cell Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.tips.2022.04.007","article-title":"Hypothalamic AMPK as a possible target for energy balance-related diseases","volume":"43","author":"Lopez","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Fukuyama, K., Motomura, E., and Okada, M. (2023). A Candidate Gliotransmitter, L-\u03b2-Aminoisobutyrate, Contributes to Weight Gain and Metabolic Complication Induced by Atypical Antipsychotics. Nutrients, 15.","DOI":"10.3390\/nu15071621"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Okada, M., Fukuyama, K., and Motomura, E. (2022). Dose-Dependent Biphasic Action of Quetiapine on AMPK Signalling via 5-HT7 Receptor: Exploring Pathophysiology of Clinical and Adverse Effects of Quetiapine. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23169103"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"623684","DOI":"10.3389\/fpsyt.2021.623684","article-title":"Current Limitations and Candidate Potential of 5-HT7 Receptor Antagonism in Psychiatric Pharmacotherapy","volume":"12","author":"Okubo","year":"2021","journal-title":"Front. Psychiatry"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0920-9964(98)00146-7","article-title":"Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro","volume":"37","author":"Bymaster","year":"1999","journal-title":"Schizophr. Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.psychres.2006.12.015","article-title":"Low baseline serotonin-2A receptors predict clinical response to olanzapine in first-episode schizophrenia patients","volume":"153","author":"Arranz","year":"2007","journal-title":"Psychiatry Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnpbp.2009.11.009","article-title":"The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain?","volume":"34","author":"Deng","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1177\/02698811211050549","article-title":"Cevimeline co-treatment attenuates olanzapine-induced metabolic disorders via modulating hepatic M3 muscarinic receptor: AMPKalpha signalling pathway in female rats","volume":"36","author":"Han","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1038\/s41380-022-01798-y","article-title":"Antipsychotics impair regulation of glucose metabolism by central glucose","volume":"27","author":"Castellani","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"155335","DOI":"10.1016\/j.metabol.2022.155335","article-title":"Modulation of hypothalamic AMPK phosphorylation by olanzapine controls energy balance and body weight","volume":"137","author":"Ferreira","year":"2022","journal-title":"Metabolism"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41380-021-01200-3","article-title":"Treatment resistance in psychiatry: State of the art and new directions","volume":"27","author":"Howes","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: Systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Br. J. Psychiatry"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41398-021-01613-2","article-title":"Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review","volume":"11","author":"Wagner","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.euroneuro.2022.03.010","article-title":"Comparative effectiveness of antipsychotic monotherapy and polypharmacy in schizophrenia patients with clozapine treatment: A nationwide, health insurance data-based study","volume":"59","author":"Joo","year":"2022","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"MY20096AH1C","DOI":"10.4088\/JCP.MY20096AH1C","article-title":"Treatment-Resistant Schizophrenia: Definition, Predictors, and Therapy Options","volume":"82","author":"Correll","year":"2021","journal-title":"J. Clin. Psychiatry"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2215-0366(15)00540-4","article-title":"Brain-imaging studies of treatment-resistant schizophrenia: A systematic review","volume":"3","author":"Mouchlianitis","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41537-019-0090-z","article-title":"The neurobiology of treatment-resistant schizophrenia: Paths to antipsychotic resistance and a roadmap for future research","volume":"6","author":"Potkin","year":"2020","journal-title":"NPJ Schizophr."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1038\/s41380-022-01572-0","article-title":"Dopaminergic dysfunction and excitatory\/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment","volume":"27","author":"Wada","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/0706743717718167","article-title":"Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis","volume":"62","author":"Siskind","year":"2017","journal-title":"Can. J. Psychiatry"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.psychres.2017.01.064","article-title":"The critical treatment window of clozapine in treatment-resistant schizophrenia: Secondary analysis of an observational study","volume":"250","author":"Yoshimura","year":"2017","journal-title":"Psychiatry Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.4088\/JCP.09m05785yel","article-title":"An algorithm-based approach to first-episode schizophrenia: Response rates over 3 prospective antipsychotic trials with a retrospective data analysis","volume":"72","author":"Agid","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","article-title":"Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): A three-phase switching study","volume":"5","author":"Kahn","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1177\/0706743718772522","article-title":"Delayed Initiation of Clozapine Continues to Be a Substantial Clinical Concern","volume":"63","author":"John","year":"2018","journal-title":"Can. J. Psychiatry"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Stepnicki, P., Kondej, M., and Kaczor, A.A. (2018). Current Concepts and Treatments of Schizophrenia. Molecules, 23.","DOI":"10.3390\/molecules23082087"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41467-017-00716-z","article-title":"Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D(2) receptors","volume":"8","author":"Sykes","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.euroneuro.2016.01.001","article-title":"The fast-off hypothesis revisited: A functional kinetic study of antipsychotic antagonism of the dopamine D2 receptor","volume":"26","author":"Sahlholm","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_95","first-page":"161","article-title":"Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action","volume":"25","author":"Kapur","year":"2000","journal-title":"J. Psychiatry Neurosci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1017\/S0033291717000435","article-title":"Antipsychotic treatment resistance in first-episode psychosis: Prevalence, subtypes and predictors","volume":"47","author":"Demjaha","year":"2017","journal-title":"Psychol. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1017\/S0033291716002014","article-title":"Two distinct patterns of treatment resistance: Clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses","volume":"46","author":"Lally","year":"2016","journal-title":"Psychol. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"505","DOI":"10.31887\/DCNS.2014.16.4\/mcarbon","article-title":"Clinical predictors of therapeutic response to antipsychotics in schizophrenia","volume":"16","author":"Carbon","year":"2014","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/schbul\/18.2.319","article-title":"A neurodevelopmental approach to the classification of schizophrenia","volume":"18","author":"Murray","year":"1992","journal-title":"Schizophr. Bull."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/13546805.2012.760917","article-title":"Clozapine and visuospatial processing in treatment-resistant schizophrenia","volume":"18","author":"Bourque","year":"2013","journal-title":"Cogn. Neuropsychiatry"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.psychres.2013.06.042","article-title":"Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: Correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses","volume":"210","author":"Balletta","year":"2013","journal-title":"Psychiatry Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"111043","DOI":"10.1016\/j.pscychresns.2020.111043","article-title":"Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: A comparison with matched treatment-responsive patients and healthy controls(\u2730,\u2730\u2730, bigstar, bigstar bigstar)","volume":"297","author":"Huang","year":"2020","journal-title":"Psychiatry Res. Neuroimaging"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Lin, A.S., Chan, H.Y., Peng, Y.C., and Chen, W.J. (2019). Severity in sustained attention impairment and clozapine-resistant schizophrenia: A retrospective study. BMC Psychiatry, 19.","DOI":"10.1186\/s12888-019-2204-6"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"103376","DOI":"10.1016\/j.ajp.2022.103376","article-title":"Developed catatonia with rhabdomyolysis and exacerbated cardiac failure upon switching from clozapine to olanzapine owing to cardiomyopathy during clozapine medication\u2014A case report","volume":"80","author":"Ito","year":"2023","journal-title":"Asian J. Psychiatr."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/s41398-022-02253-w","article-title":"Glutamatergic dysfunction in Schizophrenia","volume":"12","author":"Kruse","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s41380-018-0234-y","article-title":"mGluR5 hypofunction is integral to glutamatergic dysregulation in schizophrenia","volume":"25","author":"Wang","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature06612","article-title":"Identification of a serotonin\/glutamate receptor complex implicated in psychosis","volume":"452","author":"Ang","year":"2008","journal-title":"Nature"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.108.136861","article-title":"Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2\/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039)","volume":"326","author":"Fell","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0304-3940(00)00939-3","article-title":"Immunohistochemical localization of gamma-aminobutyric acid(B) receptor in the hippocampus of subjects with schizophrenia","volume":"283","author":"Mizukami","year":"2000","journal-title":"Neurosci. Lett."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.neulet.2005.04.025","article-title":"Immunohistochemical and immunoblot analysis of gamma-aminobutyric acid B receptor in the prefrontal cortex of subjects with schizophrenia and bipolar disorder","volume":"383","author":"Ishikawa","year":"2005","journal-title":"Neurosci. Lett."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00213-007-0845-5","article-title":"Activation of GABA(B) receptors reverses spontaneous gating deficits in juvenile DBA\/2J mice","volume":"194","author":"Bortolato","year":"2007","journal-title":"Psychopharmacology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/JCP.0000000000000270","article-title":"Effects of clozapine on perceptual abnormalities and sensory gating: A preliminary cross-sectional study in schizophrenia","volume":"35","author":"Aramaki","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1007\/s00213-016-4321-y","article-title":"Effects of acute administration of the GABA(B) receptor agonist baclofen on behavioral flexibility in rats","volume":"233","author":"Beas","year":"2016","journal-title":"Psychopharmacology"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Okada, M., Kawano, Y., Fukuyama, K., Motomura, E., and Shiroyama, T. (2020). Candidate Strategies for Development of a Rapid-Acting Antidepressant Class That Does Not Result in Neuropsychiatric Adverse Effects: Prevention of Ketamine-Induced Neuropsychiatric Adverse Reactions. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21217951"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/s41380-020-00972-4","article-title":"ZFP804A mutant mice display sex-dependent schizophrenia-like behaviors","volume":"26","author":"Huang","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neulet.2009.11.058","article-title":"The effects of glycine transporter I inhibitor, N-methylglycine (sarcosine), on ketamine-induced alterations in sensorimotor gating and regional brain c-Fos expression in rats","volume":"469","author":"Yang","year":"2010","journal-title":"Neurosci. Lett."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41380-020-0709-5","article-title":"Binding of clozapine to the GABAB receptor: Clinical and structural insights","volume":"25","author":"Nair","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"ref_118","unstructured":"Roth BL, D.J. (2023, July 27). Psychoactive Drug Screening Program (PDSP). Available online: https:\/\/pdsp.unc.edu\/databases\/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=clozapine&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/02698811221078751","article-title":"The cortical silent period in schizophrenia: A systematic review and meta-analysis focusing on disease stage and antipsychotic medication","volume":"36","author":"Miyazawa","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"108236","DOI":"10.1016\/j.pharmthera.2022.108236","article-title":"Clozapine\u2019s multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia","volume":"236","author":"Vellucci","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.neuropharm.2012.01.005","article-title":"Novel delta1-receptor agonist KNT-127 increases the release of dopamine and L-glutamate in the striatum, nucleus accumbens and median pre-frontal cortex","volume":"62","author":"Tanahashi","year":"2012","journal-title":"Neuropharmacology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/167307a0","article-title":"beta-Aminoisobutyric acid (alpha-methyl-beta-alanine); a new amino-acid obtained from human urine","volume":"167","author":"Crumpler","year":"1951","journal-title":"Nature"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.cmet.2013.12.003","article-title":"beta-Aminoisobutyric acid induces browning of white fat and hepatic beta-oxidation and is inversely correlated with cardiometabolic risk factors","volume":"19","author":"Roberts","year":"2014","journal-title":"Cell Metab."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1007\/s00125-015-3663-z","article-title":"BAIBA attenuates insulin resistance and inflammation induced by palmitate or a high fat diet via an AMPK-PPARdelta-dependent pathway in mice","volume":"58","author":"Jung","year":"2015","journal-title":"Diabetologia"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"21924","DOI":"10.1038\/srep21924","article-title":"beta-aminoisobutyric acid attenuates hepatic endoplasmic reticulum stress and glucose\/lipid metabolic disturbance in mice with type 2 diabetes","volume":"6","author":"Shi","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/JCP.0000000000000392","article-title":"Metformin for Weight Gain and Metabolic Abnormalities Associated with Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials","volume":"35","author":"Zheng","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"de Silva, V.A., Suraweera, C., Ratnatunga, S.S., Dayabandara, M., Wanniarachchi, N., and Hanwella, R. (2016). Metformin in prevention and treatment of antipsychotic induced weight gain: A systematic review and meta-analysis. BMC Psychiatry, 16.","DOI":"10.1186\/s12888-016-1049-5"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1055\/s-0044-101466","article-title":"Combination of Metformin and Lifestyle Intervention for Antipsychotic-Related Weight Gain: A Meta-Analysis of Randomized Controlled Trials","volume":"52","author":"Zheng","year":"2019","journal-title":"Pharmacopsychiatry"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Fukuyama, K., Motomura, E., and Okada, M. (2022). Brexpiprazole reduces 5-HT7 receptor function on astroglial transmission systems. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23126571"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Fukuyama, K., and Okada, M. (2021). Effects of an Atypical Antipsychotic, Zotepine, on Astroglial L-Glutamate Release through Hemichannels: Exploring the Mechanism of Mood-Stabilising Antipsychotic Actions and Antipsychotic-Induced Convulsion. Pharmaceuticals, 14.","DOI":"10.3390\/ph14111116"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ab.2016.10.017","article-title":"Gaussian and linear deconvolution of LC-MS\/MS chromatograms of the eight aminobutyric acid isomers","volume":"516","author":"Vemula","year":"2017","journal-title":"Anal. Biochem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0009-8981(74)90159-4","article-title":"The absolute configuration of \u03b2-aminoisobutyric acid in human serum and urine","volume":"50","author":"Solem","year":"1974","journal-title":"Clinica Chimica Acta"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000045507","article-title":"Specific expression of alanine-glyoxylate aminotransferase 2 in the epithelial cells of Henle\u2019s loop","volume":"83","author":"Lee","year":"1999","journal-title":"Nephron"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0021-9258(18)65261-5","article-title":"Metabolism of thymine (methyl-C14 or -2-C14) by rat liver in vitro","volume":"221","author":"Fink","year":"1956","journal-title":"J. Biol. Chem."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/mgme.1998.2737","article-title":"Methylmalonic semialdehyde dehydrogenase deficiency: Psychomotor delay and methylmalonic aciduria without metabolic decompensation","volume":"65","author":"Roe","year":"1998","journal-title":"Mol. Genet. Metab."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01801669","article-title":"Excessive excretion of beta-alanine and of 3-hydroxypropionic, R- and S-3-aminoisobutyric, R- and S-3-hydroxyisobutyric and S-2-(hydroxymethyl)butyric acids probably due to a defect in the metabolism of the corresponding malonic semialdehydes","volume":"8","author":"Pollitt","year":"1985","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/0304-4165(68)90267-5","article-title":"Beta-aminoisobutyrate-alpha-ketoglutarate transaminase in relation to beta-aminoisobutyric aciduria","volume":"156","author":"Kakimoto","year":"1968","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Kamei, Y., Hatazawa, Y., Uchitomi, R., Yoshimura, R., and Miura, S. (2020). Regulation of Skeletal Muscle Function by Amino Acids. Nutrients, 12.","DOI":"10.3390\/nu12010261"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0304-4165(90)90183-W","article-title":"Evaluation of interconversion between (R)- and (S)-enantiomers of beta-aminoisobutyrate","volume":"1035","author":"Tamaki","year":"1990","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1212\/WNL.0000000000003936","article-title":"Phenotype of GABA-transaminase deficiency","volume":"88","author":"Koenig","year":"2017","journal-title":"Neurology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0009-8981(81)90045-0","article-title":"Linear relationship between the R- and S-enantiomers of a beta-aminoisobutyric acid in human urine","volume":"116","author":"Kamerling","year":"1981","journal-title":"Clin. Chim. Acta"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0021-9258(18)81204-2","article-title":"Excretion of \u03b2-aminoisobutyric acid by man","volume":"238","author":"Armstrong","year":"1963","journal-title":"J. Biol. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0009-8981(76)90354-5","article-title":"Identification of beta-aminoisobutyric acid in uremic serum","volume":"70","author":"Gejyo","year":"1976","journal-title":"Clin. Chim. Acta"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3389\/fphys.2019.01240","article-title":"Acute Aerobic Exercise Leads to Increased Plasma Levels of R- and S-beta-Aminoisobutyric Acid in Humans","volume":"10","author":"Stautemas","year":"2019","journal-title":"Front. Physiol."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Tanianskii, D.A., Jarzebska, N., Birkenfeld, A.L., O\u2019Sullivan, J.F., and Rodionov, R.N. (2019). Beta-Aminoisobutyric Acid as a Novel Regulator of Carbohydrate and Lipid Metabolism. Nutrients, 11.","DOI":"10.3390\/nu11030524"},{"key":"ref_146","first-page":"97","article-title":"Taurine and beta-alanine act on both GABA and glycine receptors in Xenopus oocyte injected with mouse brain messenger RNA","volume":"464","author":"Horikoshi","year":"1988","journal-title":"Brain Res."},{"key":"ref_147","first-page":"919","article-title":"Pharmacology of the inhibitory glycine receptor: Agonist and antagonist actions of amino acids and piperidine carboxylic acid compounds","volume":"48","author":"Schmieden","year":"1995","journal-title":"Mol. Pharmacol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41386-018-0143-4","article-title":"Chronic clozapine treatment restrains via HDAC2 the performance of mGlu2 receptor agonism in a rodent model of antipsychotic activity","volume":"44","author":"Ibi","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/WNR.0b013e328349739b","article-title":"Evidence that clozapine directly interacts on the GABAB receptor","volume":"22","author":"Wu","year":"2011","journal-title":"Neuroreport"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/0269881120965937","article-title":"Efficacy of N-methyl-D-aspartate receptor modulator augmentation in schizophrenia: A meta-analysis of randomised, placebo-controlled trials","volume":"35","author":"Goh","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/17425255.2021.1885648","article-title":"Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: A systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Marchi","year":"2021","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11586650-000000000-00000","article-title":"Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia","volume":"25","author":"Singh","year":"2011","journal-title":"CNS Drugs"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.neuron.2005.01.035","article-title":"Cortical function: A view from the thalamus","volume":"45","author":"Basso","year":"2005","journal-title":"Neuron"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1093\/cercor\/bht173","article-title":"Convergence of cortical and sensory driver inputs on single thalamocortical cells","volume":"24","author":"Groh","year":"2014","journal-title":"Cereb. Cortex"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1152\/physrev.00048.2021","article-title":"Cortical-subcortical interactions in goal-directed behavior","volume":"103","author":"Cruz","year":"2023","journal-title":"Physiol. Rev."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/cercor\/bht296","article-title":"Thalamic relay or cortico-thalamic processing? Old question, new answers","volume":"25","author":"Ahissar","year":"2015","journal-title":"Cereb. Cortex"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"107547","DOI":"10.1016\/j.neuropharm.2019.02.029","article-title":"Effects of acute and sub-chronic administrations of guanfacine on catecholaminergic transmissions in the orbitofrontal cortex","volume":"156","author":"Okada","year":"2019","journal-title":"Neuropharmacology"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Okada, M., Fukuyama, K., Okubo, R., Shiroyama, T., and Ueda, Y. (2019). Lurasidone Sub-Chronically Activates Serotonergic Transmission via Desensitization of 5-HT1A and 5-HT7 Receptors in Dorsal Raphe Nucleus. Pharmaceuticals, 12.","DOI":"10.3390\/ph12040149"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1111\/bph.14804","article-title":"Lurasidone inhibits NMDA receptor antagonist-induced functional abnormality of thalamocortical glutamatergic transmission via 5-HT7 receptor blockade","volume":"176","author":"Okada","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1111\/bph.14974","article-title":"Pathogenesis and pathophysiology of autosomal dominant sleep-related hypermotor epilepsy with S284L-mutant alpha4 subunit of nicotinic ACh receptor","volume":"177","author":"Fukuyama","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Fukuyama, K., and Okada, M. (2020). Age-Dependent and Sleep\/Seizure-Induced Pathomechanisms of Autosomal Dominant Sleep-Related Hypermotor Epilepsy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218142"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1111\/bph.15443","article-title":"Can rodent models elucidate the pathomechanisms of genetic epilepsy?","volume":"179","author":"Okada","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Fukuyama, K., Nakano, T., Shiroyama, T., and Okada, M. (2021). Chronic Administrations of Guanfacine on Mesocortical Catecholaminergic and Thalamocortical Glutamatergic Transmissions. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084122"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Fukuyama, K., Hasegawa, T., and Okada, M. (2018). Cystine\/Glutamate Antiporter and Aripiprazole Compensate NMDA Antagonist-Induced Dysfunction of Thalamocortical L-Glutamatergic Transmission. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113645"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Okada, M., Okubo, R., and Fukuyama, K. (2019). Vortioxetine Subchronically Activates Serotonergic Transmission via Desensitization of Serotonin 5-HT1A Receptor with 5-HT3 Receptor Inhibition in Rats. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246235"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Okada, M., and Fukuyama, K. (2020). Interaction between Mesocortical and Mesothalamic Catecholaminergic Transmissions Associated with NMDA Receptor in the Locus Coeruleus. Biomolecules, 10.","DOI":"10.3390\/biom10070990"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Okada, M., Oka, T., Nakamoto, M., Fukuyama, K., and Shiroyama, T. (2020). Astroglial Connexin43 as a Potential Target for a Mood Stabiliser. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010339"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Okada, M., Matsumoto, R., Yamamoto, Y., and Fukuyama, K. (2021). Effects of Subchronic Administrations of Vortioxetine, Lurasidone, and Escitalopram on Thalamocortical Glutamatergic Transmission Associated with Serotonin 5-HT7 Receptor. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22031351"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/9\/1288\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:41:08Z","timestamp":1760128868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/9\/1288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,23]]},"references-count":168,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["biom13091288"],"URL":"https:\/\/doi.org\/10.3390\/biom13091288","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,23]]}}}